Navigation Links
Pros and Cons of Adaptive Designs: A Leisurely Conversation Between a Clinician and Two Statisticians, New Webinar Hosted by Xtalks
Date:12/17/2013

Toronto, Canada (PRWEB) December 17, 2013

This webinar will discuss adaptive designs for phase I, phase II and phase III clinical trials in oncology and will take the form of a debate between two statisticians trying to meet the requirements of an oncologist. The panel will include Dr. Marc Buyse, Founder and Chairman of IDDI, Dr. Tomasz Burzykowski, Vice President of Research for IDDI, and Dr. Everardo Saad, Scientific Director and Chairman for Dendrix and Senior Oncology Consultant for IDDI.

The pros and cons of various adaptive designs will be discussed. Topics will include continual reassessment methods for phase I trials, adaptive Bayesian designs for phase III trials, adaptive sample size increases and adaptive enrichment of phase III trials.

For more information on this webinar or to register, visit: http://xtalks.com/Pros-and-Cons-of-Adaptive-Designs.ashx.

To learn more about IDDI, visit http://www.iddi.com.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Michelle Tran (416) 977-6555 ext 224
mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/12/prweb11425544.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Adaptive Biotechnologies and Collaborators Present 16 Studies Demonstrating Clinical Significance of ImmunoSequencing at 55th Annual Meeting of the American Society for Hematology
2. Elsevier Introduces Adaptive Study Solution for Improved Learning and Memory Retention for Nursing and Health Professions
3. Adaptive Biotechnologies Publishes Gold Standard Method for Sequencing Cells of the Adaptive Immune System
4. Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
5. PI Releases High Power Piezo Amplifier to Drive Adaptive Structures, Fast Tool Servos, Vibration Cancellation Systems – Model E-482
6. Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
7. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
8. “The New Health Conversation” to Premiere on PBS
9. GMO Answers Invites Consumers to Join the Online Conversation during GMO Awareness Month in October
10. Plant Biotechnology Companies Begin New Conversation about GMOs and How our Food is Grown
11. Intrinsically disordered proteins: A conversation with Rohit Pappu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... VILLAGE, Calif. , March 24, 2017   ... dermatology and aesthetics company, today announced that Richard ... Officer, effective March 24.   Peterson, who brings ... succeed John Smither , who is retiring at ... Sienna in an advisory capacity. Peterson joins Sienna from ...
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics ... DCVax® personalized immune therapies for solid tumor cancers, ... $7.5 million financing it announced last Friday, March ... to several institutional investors securities totaling 28,843,692 shares, ... share, and 10,000,000 shares of Class C Warrants ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... Orleans, La. (PRWEB) , ... March 23, 2017 ... ... real-time, industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd ... APMT customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
Breaking Biology News(10 mins):